Rare Genetic Mutations Linked To Bipolar Disorder
Monday, January 2, 2012
An international team of scientists, led by researchers at the University of California, San Diego college of medication, reports that abnormal sequences of DNA referred to as rare copy variety variants, or CNVs, seem to play a major role within the risk for early onset bipolar disorder.
The findings were printed within the Dec. twenty two issue of the journal Neuron.
CNVs are genomic alterations during which there are too few or too several copies of sections of DNA. Researchers have known that spontaneously occurring (de novo) CNVs - genetic mutations not inherited from oldsters - considerably increase the danger for a few neuropsychiatric conditions, like schizophrenia or the autism spectrum disorders. however their role was unclear in bipolar disorder, previously referred to as manic depression.
Principal investigator Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular drugs at UC San Diego's Institute of Genomic drugs, and colleagues, found that de novo CNVs contribute vital genetic risk in concerning five % of early onset bipolar disorder, that seems in childhood or early adulthood.
In different words, said the study's initial author Dheeraj Malhotra, assistant project scientist in Sebat's lab, "having a de novo mutation will increase the possibilities of getting an earlier onset of disease."
The cause or causes of bipolar disorder stay unclear. there's a transparent genetic part - the disease runs in families - however previous studies that have targeted mainly on common inherited variants have met with restricted success in identifying key susceptibility genes.
Malhotra said that - whereas the findings don't conclusively pinpoint a particular gene or genomic region -- the new findings show "convincing" proof that rare copy variety mutations strongly contribute to the event of early onset bipolar disorder. He added that sequencing of complete genomes or exomes of huge variety of bipolar families is required to work out the entire genetic contribution of all kinds of de novo mutation to risk for bipolar disorder.
Funding for this analysis came, in part, from the National Institutes of Health, Ted and Vada Stanley, the Beyster family foundation, Wellcome Trust, Science Foundation eire, the Sidney R. Baer, Jr. Foundation and therefore the Essel Foundation.
Co-authors of the study are Shane McCarthy, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory; Jacob J. Michaelson, Beyster Center for Genomics of Psychiatric Diseases and UC San Diego Department of Psychiatry; Vladimir Vacic, Department of laptop Science, Columbia University and Stanley Institute for Cognitive Genomics; Katherine E. Burdick, Mount Sinai college of Medicine; Seungtai Yoon, Seaver Autism Center, Mount Sinai college of Medicine; Sven Cichon, Department of Genomics, Life and Brain Center, Institute of Human Genetics, University of Bonn and Institute of Neuroscience and Medicine; Aiden Corvin and Michael Gill, Neuropsychiatric Genetics analysis cluster, Institute of Molecular drugs and Department of Psychiatry, Trinity faculty Dublin; Sydney Gary, Stanley Institute for Cognitive Genomics, Elliot S. Gershon, Department of Psychiatry and Behavioral Neuroscience, University of Chicago; Maria Karayiorgou, Department of Psychiatry, Columbia University; John R. Kelsoe, Department of Psychiatry and Institute for Genomic drugs, UC San Diego; Olga Krastoshevsky, Verena Krause and Deborah L. Levy, Department of Psychiatry, McLean Hospital; Ellen Leibenluft, Section on Bipolar Spectrum Disorders, Emotion and Development Branch, NIMH; Vladimir Makarov, Seaver Autism Center and Stanley Institute for Cognitive Genomics; Abhishek Bhandari, Beyster Center for Genomics of Psychiatric Diseases, UC San Diego Department of Psychiatry and Stanley Institute for Cognitive Genomics; Anil K. Malhotra, Zucker Hillside Hospital; Francis J. McMahon, Genetic Basis of Moods and Anxiety Disorders, NIMH; Markus M. Nothen, Department of Genomics, Life and Brain Center, Institute of Human Genetics, University of Bonn and German Center for Neurodegenerative Diseases; James B. Potash, Department of Psychiatry, University of Iowa, Marcella Rietschel, Central Institute of Mental Health, University of Heidelberg and Thomas G. Schulze, Department of Psychiatry and Psychotherapy, George-August University, Germany.
The findings were printed within the Dec. twenty two issue of the journal Neuron.
CNVs are genomic alterations during which there are too few or too several copies of sections of DNA. Researchers have known that spontaneously occurring (de novo) CNVs - genetic mutations not inherited from oldsters - considerably increase the danger for a few neuropsychiatric conditions, like schizophrenia or the autism spectrum disorders. however their role was unclear in bipolar disorder, previously referred to as manic depression.
Principal investigator Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular drugs at UC San Diego's Institute of Genomic drugs, and colleagues, found that de novo CNVs contribute vital genetic risk in concerning five % of early onset bipolar disorder, that seems in childhood or early adulthood.
In different words, said the study's initial author Dheeraj Malhotra, assistant project scientist in Sebat's lab, "having a de novo mutation will increase the possibilities of getting an earlier onset of disease."
The cause or causes of bipolar disorder stay unclear. there's a transparent genetic part - the disease runs in families - however previous studies that have targeted mainly on common inherited variants have met with restricted success in identifying key susceptibility genes.
Malhotra said that - whereas the findings don't conclusively pinpoint a particular gene or genomic region -- the new findings show "convincing" proof that rare copy variety mutations strongly contribute to the event of early onset bipolar disorder. He added that sequencing of complete genomes or exomes of huge variety of bipolar families is required to work out the entire genetic contribution of all kinds of de novo mutation to risk for bipolar disorder.
Funding for this analysis came, in part, from the National Institutes of Health, Ted and Vada Stanley, the Beyster family foundation, Wellcome Trust, Science Foundation eire, the Sidney R. Baer, Jr. Foundation and therefore the Essel Foundation.
Co-authors of the study are Shane McCarthy, Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory; Jacob J. Michaelson, Beyster Center for Genomics of Psychiatric Diseases and UC San Diego Department of Psychiatry; Vladimir Vacic, Department of laptop Science, Columbia University and Stanley Institute for Cognitive Genomics; Katherine E. Burdick, Mount Sinai college of Medicine; Seungtai Yoon, Seaver Autism Center, Mount Sinai college of Medicine; Sven Cichon, Department of Genomics, Life and Brain Center, Institute of Human Genetics, University of Bonn and Institute of Neuroscience and Medicine; Aiden Corvin and Michael Gill, Neuropsychiatric Genetics analysis cluster, Institute of Molecular drugs and Department of Psychiatry, Trinity faculty Dublin; Sydney Gary, Stanley Institute for Cognitive Genomics, Elliot S. Gershon, Department of Psychiatry and Behavioral Neuroscience, University of Chicago; Maria Karayiorgou, Department of Psychiatry, Columbia University; John R. Kelsoe, Department of Psychiatry and Institute for Genomic drugs, UC San Diego; Olga Krastoshevsky, Verena Krause and Deborah L. Levy, Department of Psychiatry, McLean Hospital; Ellen Leibenluft, Section on Bipolar Spectrum Disorders, Emotion and Development Branch, NIMH; Vladimir Makarov, Seaver Autism Center and Stanley Institute for Cognitive Genomics; Abhishek Bhandari, Beyster Center for Genomics of Psychiatric Diseases, UC San Diego Department of Psychiatry and Stanley Institute for Cognitive Genomics; Anil K. Malhotra, Zucker Hillside Hospital; Francis J. McMahon, Genetic Basis of Moods and Anxiety Disorders, NIMH; Markus M. Nothen, Department of Genomics, Life and Brain Center, Institute of Human Genetics, University of Bonn and German Center for Neurodegenerative Diseases; James B. Potash, Department of Psychiatry, University of Iowa, Marcella Rietschel, Central Institute of Mental Health, University of Heidelberg and Thomas G. Schulze, Department of Psychiatry and Psychotherapy, George-August University, Germany.
0 comments:
Post a Comment